Poland· PL-100026841
Gliatilin
A choline alfoscerate product containing cholini alphosceras, registered in Poland by Italfarmaco S.p.A..
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Cholini alphosceras
- Manufacturer
- Italfarmaco S.p.A.
- Country
- Poland (PL)
- ATC code
- N07AX02
- ATC class
- Choline alfoscerate
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909990233816
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under N07AX02
Choline alfoscerate, as other registers publish it.
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Italy · Delecit, Gliatilin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/55388e27-b97f-42d4-9ef5-9330b6782dd9 GET /v1/drugs/55388e27-b97f-42d4-9ef5-9330b6782dd9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki miękkie",
"source": "urpl",
"strength": "400 mg",
"packaging": "05909990233816 ¦ Rp ¦ 4305\n14 kaps.",
"substance": "Cholini alfosceras 400 mg",
"common_name": "Cholini alphosceras",
"pl_product_id": "100026841",
"pozwolenie_nr": "02338",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about choline alfoscerate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.